Released on = September 26, 2006, 4:47 am

Press Release Author = cinzia bersani

Industry = Biotech

Press Release Summary = A NEW TECHNOLOGY FOR TRANSFECTING ADHERENT CELLS ON MICROCHIP

Press Release Body = Colleretto Giacosa (TO) Italy, September 27, 2006

Narvalus Srl is pleased to announce the conclusion of all the prototype activities
of its proprietary technology which lead to the definition of "T2 Target
Transfector".

The "T2 Target Transfector" will be presented today at the Bioindustry Park Canavese
SpA.
Narvalus technology consists of electroporating single cells cultivated on microchip
through micro electrodes positioned on the chip itself.

Compared to the traditional methods, this technology and its specific equipment,
allows individual and immediate response. The ability to address single cells, the
high flexibility in the pulse design and the instantaneous experiment read-out,
enables the operator to obtain a quick optimization of the electroporation protocol.
The T2 technology gives high reproducibility of the transfection rates, allowing
furthermore the check of each single cell behaviour after transfection.

The technology has been tested on different cell lines and it has been shown to be
widely versatile since the transfection method could be easily defined and modified
by the operator: it has been validated for the introduction of dyes,
oligonucleotides (extremely appropriate for siRNA studies) and plasmids.

In the biotechnological field, electroporation is employed for cell transfection and
represents the basic process of the biotechnological techniques.

The "T2 Target Transfector" represents in this field a relevant innovation and it
gives unexplored opportunities both for research in molecular biology and
diagnostic/industrial applications.

"The T2 Target Transfector presented today at the Bioindustry Park Canavese is an
important result for our research group," says Manfredi Manfrin Ceo of the Narvalus
Biotech Srl" and we hope it will quickly find applications at academic and
industrial research labs thanks to its potential versatility and simplicity".

Narvalus Biotech
Narvalus Biotech srl was constituted in 2005, (operative since autumn 2005),
located at the Bioindustry Park Incubator, financially supported by Eporgen Venture
SpA.

The technology, originally created and developed at Rovereto (Biosilab Srl), has
been selected through the Discovery program with the aim of setting up Narvalus
Company whose focus consists in transferring the technology from lab to market.

Contacts:
Narvalus Biotech srl
www.narvalusbiotech.com
cinzia.bersani@narvalusbiotech.com


Web Site = http://www.narvalusbiotech.com

Contact Details = Narvalus Biotech srl
via Ribes 5
10010 Colleretto Giacosa
Tel 0039.0125.538142
Fax 0039.0125.538740